AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.140
-0.003 (-1.96%)
At close: Feb 21, 2025, 4:00 PM
0.135
-0.005 (-3.50%)
After-hours: Feb 21, 2025, 7:51 PM EST
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $35.00K in the quarter ending September 30, 2024, a decrease of -23.91%. This brings the company's revenue in the last twelve months to $190.00K, down -1.55% year-over-year. In the year 2023, AIM ImmunoTech had annual revenue of $202.00K with 43.26% growth.
Revenue (ttm)
$190.00K
Revenue Growth
-1.55%
P/S Ratio
38.03
Revenue / Employee
$6,786
Employees
28
Market Cap
8.82M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
Dec 31, 2019 | 140.00K | -227.00K | -61.85% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AIM News
- 11 days ago - AIM ImmunoTech Releases Virtual Investor “What This Means Segment” - GlobeNewsWire
- 11 days ago - AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - GlobeNewsWire
- 15 days ago - AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting - Business Wire